[go: up one dir, main page]

NO20080770L - N-dihydroksyalkylsubstituert 2-oksimidazolderivat - Google Patents

N-dihydroksyalkylsubstituert 2-oksimidazolderivat

Info

Publication number
NO20080770L
NO20080770L NO20080770A NO20080770A NO20080770L NO 20080770 L NO20080770 L NO 20080770L NO 20080770 A NO20080770 A NO 20080770A NO 20080770 A NO20080770 A NO 20080770A NO 20080770 L NO20080770 L NO 20080770L
Authority
NO
Norway
Prior art keywords
agent
therapeutic agent
antidepressant
pain reliever
carbon atoms
Prior art date
Application number
NO20080770A
Other languages
English (en)
Inventor
Masaya Hashimoto
Yoshikazu Iwasawa
Hiroshi Kawamoto
Hisashi Ohta
Satoshi Ozaki
Takeshi Sagara
Hiroki Sakoh
Atsushi Satoh
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20080770L publication Critical patent/NO20080770L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er ment å tilveiebringe en forbindelse representert ved formel (I) hvori R representerer en alkylgruppe som har 1 - 6 karbonatomer substituert med 2 hydroksylgrupper, Cy representerer en bi- eller trisyklisk, alifatisk karboksylgruppe som har 6-10 karbonatomer som kan ha en substituent i noen tilfeller. Forbindelsen virker som en nociceptinreseptorantagonist og er nyttig som for eksempel et narkotisk smertestillende resistensmotvirkningsmiddel, et motvirkningsmiddel for narkotisk smertelindringsavhengighet eller abstinenssyndrom, et smertestillende forsterkningsmiddel, et antifetningsmiddel eller appetittkontrollmiddel, et middel for forbedring eller hindring av reduksjon av læreevne og hukommelsesevne eller symptomer på demens, et middel for forbedring av kognitiv funksjon i det utviklingsmessige stadiet, et terapeutisk middel for schizofreni, et terapeutisk middel for neurodegenerativ sykdom i tilbakegang, et antidepresjonsmiddel eller et middel for kontroll av følelser, et terapeutisk middel eller forebyggende middel for diabetes insipidus, et terapeutisk middel eller forebyggende middel for polyuri, et terapeutisk middel for hypopiese og dets like.
NO20080770A 2005-07-13 2008-02-12 N-dihydroksyalkylsubstituert 2-oksimidazolderivat NO20080770L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005204264 2005-07-13
PCT/JP2006/314122 WO2007007890A1 (ja) 2005-07-13 2006-07-11 Ｎ－ジヒドロキシアルキル置換２－オキソイミダゾール誘導体

Publications (1)

Publication Number Publication Date
NO20080770L true NO20080770L (no) 2008-04-11

Family

ID=37637260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080770A NO20080770L (no) 2005-07-13 2008-02-12 N-dihydroksyalkylsubstituert 2-oksimidazolderivat

Country Status (23)

Country Link
EP (1) EP1914232B1 (no)
JP (1) JP4748162B2 (no)
KR (1) KR20080033262A (no)
CN (1) CN101223158B (no)
AR (1) AR054816A1 (no)
AU (1) AU2006267391B2 (no)
BR (1) BRPI0613109A2 (no)
CA (1) CA2614688A1 (no)
CR (1) CR9692A (no)
DE (1) DE602006018950D1 (no)
DO (1) DOP2006000165A (no)
EC (1) ECSP088096A (no)
ES (1) ES2355580T3 (no)
IL (1) IL188418A0 (no)
MA (1) MA29738B1 (no)
NI (1) NI200800003A (no)
NO (1) NO20080770L (no)
NZ (1) NZ565026A (no)
PE (1) PE20070176A1 (no)
RU (1) RU2414456C2 (no)
TW (1) TW200740436A (no)
WO (1) WO2007007890A1 (no)
ZA (1) ZA200711025B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033780A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
RU2010114003A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
PE20130775A1 (es) * 2010-05-27 2013-07-21 Targacept Inc Antagonistas no competitivos de receptores nicotinicos
PT3345907T (pt) * 2015-09-01 2020-06-23 Taiho Pharmaceutical Co Ltd Compostos de pirazolo[3,4-d]pirimidina ou sais dos mesmos
EP4345096A4 (en) * 2021-07-14 2024-11-13 Yichang Humanwell Pharmaceutical Co., Ltd. Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786997A4 (en) * 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANAGONISTS
AU2388697A (en) * 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
DE69826278T2 (de) * 1997-05-30 2005-11-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazol-derivate
EP1049689B1 (en) * 1998-01-19 2002-06-26 Pfizer Inc. 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
EP1242085B1 (en) * 1999-12-06 2005-08-24 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity

Also Published As

Publication number Publication date
CN101223158B (zh) 2013-01-09
EP1914232B1 (en) 2010-12-15
CN101223158A (zh) 2008-07-16
JPWO2007007890A1 (ja) 2009-01-29
NZ565026A (en) 2010-09-30
NI200800003A (es) 2008-07-21
AR054816A1 (es) 2007-07-18
IL188418A0 (en) 2008-11-03
AU2006267391B2 (en) 2011-12-08
EP1914232A1 (en) 2008-04-23
RU2008105396A (ru) 2009-08-20
DE602006018950D1 (de) 2011-01-27
DOP2006000165A (es) 2007-02-28
KR20080033262A (ko) 2008-04-16
CR9692A (es) 2008-02-21
EP1914232A4 (en) 2009-10-28
RU2414456C2 (ru) 2011-03-20
BRPI0613109A2 (pt) 2012-12-04
TW200740436A (en) 2007-11-01
JP4748162B2 (ja) 2011-08-17
MA29738B1 (fr) 2008-09-01
ZA200711025B (en) 2008-12-31
WO2007007890A1 (ja) 2007-01-18
ES2355580T3 (es) 2011-03-29
CA2614688A1 (en) 2007-01-18
AU2006267391A1 (en) 2007-01-18
ECSP088096A (es) 2008-02-20
PE20070176A1 (es) 2007-03-09

Similar Documents

Publication Publication Date Title
TW200505919A (en) DPP-IV inhibitors
WO2006103120A3 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
ATE438402T1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
DE602005013822D1 (de) Cycloalkylaminderivate
NO20080770L (no) N-dihydroksyalkylsubstituert 2-oksimidazolderivat
TW200736248A (en) Compounds for the treatment of inflammatory disorders
HK1100426A1 (en) Thiadiazolidinones as gsk-3 inhibitors
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
ATE544756T1 (de) Substituierte carbinolverbindungen
WO2007014762A3 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
BRPI0615614A2 (pt) compostos orgánicos
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
TW200631580A (en) Substituted benzoquinolizine derivatives
MX2010001131A (es) Metodo para controlar ectoparasitos.
EP1914229A4 (en) NOVEL CERCOSPORAMIDE DERIVATIVES
BR0308643A (pt) Composto do derivado do ácido piridobenzoxazina carboxìlico e agente antibacteriano contendo o mesmo
TNSN05197A1 (en) Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation -and immunologically- mediated diseases
NO20092804L (no) Kondensert, substituert aminopyrrolidinderivat
BR0210222A (pt) Derivado de benzoxazepina, composição farmacêutica, uso de um derivado de benzoxazepina, e, método para tratar uma doença neurológica ou distúrbio psiquiátrico
WO2008038092A3 (en) Substituted piperidinophenyl oxazolidinones
MX2008002073A (es) Compuestos para el tratamiento de trastornos inflamatorios.
TW200612924A (en) Oxazolidinones containing oxindoles as antibacterial agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application